Health Catalyst Inc (HCAT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Outlook

GuruFocus.com11-07

Total Revenue: $76.4 million for Q3 2024, a 3% increase year-over-year. Adjusted EBITDA: $7.3 million for Q3 2024, exceeding the midpoint of guidance. Technology Revenue: $48.11 million for Q3 2024, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481923940?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/v93DANMwJOzKwKdHUeTK6Q--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/bf667689e37017f7d5fe213cf63c1590","is_english":true,"pubTime":"2024-11-07 15:22","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481923940","market":"us","top_or_hot":-1,"title":"Health Catalyst Inc (HCAT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Outlook","media":"GuruFocus.com","content":"<div>\n<p>Total Revenue: $76.4 million for Q3 2024, a 3% increase year-over-year.\nAdjusted EBITDA: $7.3 million for Q3 2024, exceeding the midpoint of guidance.\nTechnology Revenue: $48.11 million for Q3 2024, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/health-catalyst-inc-hcat-q3-072248159.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Catalyst Inc (HCAT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Catalyst Inc (HCAT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 15:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/health-catalyst-inc-hcat-q3-072248159.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Total Revenue: $76.4 million for Q3 2024, a 3% increase year-over-year.\nAdjusted EBITDA: $7.3 million for Q3 2024, exceeding the midpoint of guidance.\nTechnology Revenue: $48.11 million for Q3 2024, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/health-catalyst-inc-hcat-q3-072248159.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HCAT","symbol_name":"Health Catalyst, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/health-catalyst-inc-hcat-q3-072248159.html","article_id":"2481923940","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/v93DANMwJOzKwKdHUeTK6Q--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/bf667689e37017f7d5fe213cf63c1590"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481923940","pubTimestamp":1730964168,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Total Revenue: $76.4 million for Q3 2024, a 3% increase year-over-year.Adjusted EBITDA: $7.3 million for Q3 2024, exceeding the midpoint of guidance.Technology Revenue: $48.11 million for Q3 2024, representing 6% growth year-over-year.Professional Services Revenue: $27.7 million for Q3 2024, roughly flat year-over-year.Total Adjusted Gross Margin: 48% for Q3 2024, an increase of approximately 70 basis points year-over-year.Adjusted Technology Gross Margin: 65% for Q3 2024, a decrease of approximately 330 basis points year-over-year.Adjusted Professional Services Gross Margin: 17% for Q3 2024, an increase of approximately 550 basis points year-over-year.Adjusted Total Operating Expenses: $29 million for Q3 2024, 38% of revenue.Adjusted Net Income Per Share: $0.07 for Q3 2024.Cash, Cash Equivalents, and Short-term Investments: $387.2 million as of Q3 2024.Financial Guidance for Q4 2024: Total revenue between $78 million and $84 million; adjusted EBITDA between $6.8 million and $8.8 milli","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HCAT":"Health Catalyst, Inc."},"translate_title":"Health Catalyst Inc(HCAT)2024年第三季度收益看涨期权亮点：收入增长和战略前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCAT":1},"content_text":"Total Revenue: $76.4 million for Q3 2024, a 3% increase year-over-year.\nAdjusted EBITDA: $7.3 million for Q3 2024, exceeding the midpoint of guidance.\nTechnology Revenue: $48.11 million for Q3 2024, representing 6% growth year-over-year.\nProfessional Services Revenue: $27.7 million for Q3 2024, roughly flat year-over-year.\nTotal Adjusted Gross Margin: 48% for Q3 2024, an increase of approximately 70 basis points year-over-year.\nAdjusted Technology Gross Margin: 65% for Q3 2024, a decrease of approximately 330 basis points year-over-year.\nAdjusted Professional Services Gross Margin: 17% for Q3 2024, an increase of approximately 550 basis points year-over-year.\nAdjusted Total Operating Expenses: $29 million for Q3 2024, 38% of revenue.\nAdjusted Net Income Per Share: $0.07 for Q3 2024.\nCash, Cash Equivalents, and Short-term Investments: $387.2 million as of Q3 2024.\nFinancial Guidance for Q4 2024: Total revenue between $78 million and $84 million; adjusted EBITDA between $6.8 million and $8.8 million.\nFull Year 2024 Guidance: Total revenue between $305 million and $311 million; adjusted EBITDA between $25 million and $27 million.\nOperating Cash Flow: $18.1 million through Q3 2024.\n\n\nWarning! GuruFocus has detected 3 Warning Signs with HCAT.\n\nRelease Date: November 06, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nHealth Catalyst Inc (NASDAQ:HCAT) reported total revenue of $76.4 million and adjusted EBITDA of $7.3 million for Q3 2024, both exceeding the midpoint of previous guidance.\nThe company anticipates 2024 revenue to be between $305 million and $311 million, with adjusted EBITDA expectations raised to between $25 million and $27 million.\nHealth Catalyst Inc (NASDAQ:HCAT) has seen strong demand for its Ignite platform, with successful client migrations and new client acquisitions contributing to growth.\nThe company has been recognized as one of the best workplaces in healthcare by Fortune and received other accolades, highlighting its positive work environment and industry reputation.\nHealth Catalyst Inc (NASDAQ:HCAT) has a robust pipeline and expects to return to double-digit revenue growth in 2025, driven by new client additions, existing client expansions, and strategic acquisitions.\n\n Negative Points \n\nThe company faces challenges with longer implementation timelines for international and health information exchange contracts, which could delay revenue recognition.\nThere are ongoing costs associated with the deployment of the Ninja Universe platform and migration from DOS to Ignite, impacting technology gross margins.\nProfessional services revenue remained flat year-over-year, and there are pressures on professional services gross margins due to incremental resourcing and seasonal expenses.\nHealth Catalyst Inc (NASDAQ:HCAT) is experiencing lower bookings in certain areas due to a strategic focus on higher-margin solutions, which may impact near-term revenue.\nThe company is still learning and adjusting cost structures in new areas like ambulatory operations within its tech-enabled managed services (TEMS), which could affect profitability.\n\n Q & A Highlights \nQ: Can you provide more color on the pipeline and sales opportunities for achieving double-digit growth in 2025? A: Dan Burton, CEO, explained that Health Catalyst is on track for the best year in terms of net new client additions, with expectations of adding new platform subscription clients in the low 20s. The average ARR for these new clients is expected to be between $400,000 and $1 million. The company is also seeing strong expansion with existing clients, particularly in high-margin areas, and is leveraging inorganic activities through acquisitions to drive growth.\nQ: Are you expecting a similar bookings mix in 2025 as in 2024, with more bookings from international and information exchange customers? A: Dan Burton, CEO, noted strong performance in 2024 among international and health information exchange clients, which tend to be higher-margin expansions. These clients contribute to recurring revenue and provide long-term advantages. The company anticipates continuing this trend in 2025, with a meaningful pipeline of opportunities in these areas.\nQ: Can you explain the growth related to nonrecurring services contracts and their impact on 2025? A: Dan Burton, CEO, stated that nonrecurring services contracts are primarily with existing clients, both in the U.S. and internationally. These contracts are often related to ongoing clinical, operational, and financial improvement initiatives. While the contracts are nonrecurring, they often lead to ongoing spend, contributing to growth.\nQ: What synergies does the Enterprise acquisition bring to Health Catalyst's core platform? A: Dan Burton, CEO, highlighted that cybersecurity is a critical area for clients, and the acquisition of Enterprise allows Health Catalyst to offer robust security infrastructure as part of its Ignite solution. This complements Health Catalyst's existing offerings and addresses a significant client need.\nQ: How are you managing the elevated costs related to TEMS contracts, and what is the outlook for gross margin expansion? A: Dan Burton, CEO, mentioned that while there are elevated costs in new areas like ambulatory operations, the company is seeing meaningful margin improvement in areas with more experience, such as chart abstraction and data management. The company is leveraging AI to drive efficiency gains and expects continued margin improvement in these areas.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481923940"}